GenomeWeb

This story has been corrected to reflect that Seer Chairman and CEO Omid Farokhzad did not raise his offer to $2.55 per share as originally stated but rather that he improved the offer's contigent value rights. We regret the error. NEW YORK – Seer said Thursday that Chairman and CEO Omid Farokhzad has submitted a new, improved bid to acquire the company. Farokhzad's bid maintains his previous offer of $2.45 per share but boosts the contingent value rights included as part of the offer.

NEW YORK – Tempus AI saw growth in its oncology business provide significant lift to second-quarter revenues and expects growth to continue for at least the next few years, the firm said on Thursday. Meanwhile, its oncology testing products have been gaining regulatory approval and its minimal residual disease business is benefitting from its recent deal to acquire Personalis.

NEW YORK – Nabsys said on Friday that it has entered into a multi-year research collaboration with the Indiana University School of Medicine to develop and evaluate Electronic Genome Mapping (EGM) applications for hematologic malignancies.

Scale AI: Francis deSouza Former Illumina CEO Francis deSouza has been appointed as CEO of Scale AI, effective Aug. 10. Most recently, he was chief operating officer and president of security products of Google Cloud. Before that, he was president and CEO of Illumina, and prior to that, president of products and services at Symantec. He holds bachelor's and master's degrees in electrical engineering and computer science from the Massachusetts Institute of Technology.

NEW YORK – Seer said Thursday that Chairman and CEO Omid Farokhzad has submitted a new, higher bid to acquire the company. Farokhzad's bid, in which he raised his offer to $2.55 per share from his previous offer of $2.45 per share, came a day after Seer shareholders Bradley Radoff and Michael Torok — part of the Radoff-JEC Group, which owns about 7.7 percent of the proteomics firm — raised their own takeover offer from $2.45 to $2.55 per share.

NEW YORK – GenomOncology announced Thursday that it will integrate Pacific Biosciences' HiFi whole-genome sequencing secondary analysis pipeline with its Pathology Workbench reporting platform. Translating long-read WGS outputs into clinician-ready reports "has remained a persistent operational challenge for labs," Cleveland-based GenomOncology said in a statement.

Marker by Labcorp Genetic Health Panel Laboratory Corporation of American has launched the Marker by Labcorp Genetic Health Panel to help consumers better understand inherited risks associated with more than 100 medically actionable conditions. The panel is available through Labcorp OnDemand and analyzes 163 genes that are associated with hereditary cancer, cardiovascular conditions, and metabolic conditions.

NEW YORK — ABL Diagnostics this week announced the CE-IVD registration of its molecular tests for HIV-1, key respiratory pathogens, and viral meningitis. The French company also said that it has recently amended an equity line and share loan agreement with two major stockowners.

NEW YORK – Diasorin reported on Friday that its second quarter revenue increased 9 percent year over year on a reported basis, or 4 percent at constant exchange rates, in part due to strong sales in immunodiagnostics. Excluding the Chinese market and the respiratory molecular business, revenue in Q2 was up 5 percent at constant exchange rates.

NEW YORK – Castle Biosciences said this week that it is raising its 2026 revenue guidance, following strong second-quarter financial results. The firm now expects $365 million to $375 million in revenue this year, up from a previous range of $345 million to $355 million. For the quarter ended June 30, the Friendswood, Texas-based diagnostics firm reported $103.5 million in revenue, up 20 percent from $86.2 million in Q2 2025 and beating the consensus Wall Street estimate of $86.2 million.